Effects of abiraterone: A Synthesis of Findings from 12 Studies

  1. Home
  2. Effects of abiraterone
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of abiraterone: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of abiraterone: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Abiraterone is a medication used to treat metastatic castration-resistant prostate cancer (mCRPC). 7 It works by blocking the production of testosterone, a hormone that fuels the growth of prostate cancer cells. 6 Abiraterone has been shown to improve survival in patients with mCRPC. 7

Abiraterone is generally well tolerated, but it can cause side effects. 7 Common side effects include high blood pressure, low potassium levels, and liver enzyme elevations. 11 Abiraterone can also cause kidney problems, but this is rare. 11

Food can affect the absorption of abiraterone. 9 Eating a high-fat meal can increase the amount of abiraterone in the blood, which may increase the risk of side effects. 9 It is important to talk to your doctor about the best way to take abiraterone. 3

Benefits and Risks

Benefit Summary

Abiraterone is a potentially effective treatment for mCRPC. 7 It may improve survival, shrink tumors, slow the progression of bone metastasis, and reduce the risk of skeletal-related events. 10 Abiraterone can also improve kidney function in some patients. 11

Risk Summary

Abiraterone can cause side effects, but these are generally manageable. 7 Common side effects include high blood pressure, low potassium levels, and liver enzyme elevations. 11 Food can affect the absorption of abiraterone. 9 Eating a high-fat meal can increase the amount of abiraterone in the blood, which may increase the risk of side effects. 9

Comparison Across Studies

Commonalities Across Studies

These studies consistently show abiraterone to be a promising treatment for mCRPC, with various benefits in improving survival, tumor reduction, and management of bone metastasis. 7 10

Differences Across Studies

The studies reviewed in this meta-analysis provide varying insights into the specific side effect profiles of abiraterone. 7 This is likely due to differences in study design, participant characteristics, and other factors. 7

Consistency and Contradictions in Results

While several studies highlight the effectiveness of abiraterone for mCRPC, some inconsistencies exist concerning its side effect profile. 7 Further research is needed to clarify the potential risks associated with abiraterone use. 7

Implications for Real-World Application

It is crucial for patients to discuss any potential risks associated with abiraterone with their doctor before starting treatment. 7 The doctor will help determine the best treatment plan considering the patient's medical history, allergies, and other health conditions. 3

Limitations of Current Research

There is a limited number of studies directly comparing the side effect profiles of abiraterone and other mCRPC treatments like enzalutamide. 7 Additionally, these studies may not account for factors such as dosage, duration of treatment, and patient characteristics, which could influence side effects. 7

Future Research Directions

Further research is necessary to better understand the side effect profile of abiraterone. 7 Future studies should include a larger number of participants, consider factors such as dosage and duration of treatment, and account for patient characteristics. 7 More research is also needed to determine the long-term effects of abiraterone. 7

Conclusion

Abiraterone is a promising treatment for mCRPC, but it is essential to understand the potential side effects. 7 The benefits and risks of abiraterone should be carefully considered before starting treatment. 7 It is important to talk to your doctor about any concerns you may have. 3

Literature analysis of 12 papers
Positive Content
11
Neutral Content
0
Negative Content
1
Article Type
2
1
1
3
12
1.

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.

Author: WerutskyGustavo, MalufFernando Cotait, CronembergerEduardo Henrique, Carrera SouzaVinicius, Dos Santos MartinsSuelen Patricia, PeixotoFábio, SmaletzOren, SchutzFábio, HerchenhornDaniel, SantosTelma, Mavignier CarcanoFlavio, Queiroz MunizDavid, Nunes FilhoPaulo R S, ZaffaroniFacundo, BarriosCarlos, FayAndré

Prostate cancer treatment
Side effects

This study explores the potential of abiraterone acetate with prednisone (AAP) and apalutamide, both alone and in combination, as hormonal therapies for advanced prostate cancer. The researchers hypothesize that these treatments may be effective in reducing castration-associated side effects, such as sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Instrumental and transcriptome analysis reveals the chemotherapeutic effects of doxorubicin-loaded black phosphate nanosheets on abiraterone-resistant prostate cancer.

Author: XuHaoyang, LiuJiaqi, LiXiangkai, LiJiawei, LinXiao, LiZhuowei, DouTong, GaoLi, LiRong, LaiKeng Po

Prostate cancer treatment

Abiraterone acetate is an effective treatment for prostate cancer, but resistance develops in 20-40% of patients. This study aimed to understand the mechanisms of abiraterone resistance and investigate the therapeutic potential of black phosphorus nanosheets (BPNS). BPNS reduced the proliferation and migration of abiraterone-resistant prostate cancer cells.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.

Author: SantiniDaniele, CinieriSaverio, GasparroDonatello, BordonaroRoberto, GuglielminiPamela Francesca, ChiuriVincenzo Emanuele, D'AngelilloRolando M, CeresoliGiovanni Luca, FagnaniDaniele, AcquatiMirko, MencoboniManlio, LanzettaGaetano, SartoriDonata, CarliniPaolo, PanebiancoFabiana, BeccagliaPatrizia, ProcopioGiuseppe

Treats mCRPC

Four bone turnover biomarkers (BTMs) were measured during abiraterone acetate plus prednisone (AAP) treatment in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) men failing androgen-deprivation therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.

Author: LeeHsiang Ying, ChenHsiao-Ling, TeohJeremy Yuen-Chun, ChenTun-Chieh, HaoShao-Yuan, TsaiHsin-Yi, HuangWei-Hsuan, JuanYung-Shun, ChengHao-Min, ChangHsiu-Mei

Cardiac disorders
Hypertension

Abiraterone is associated with an increased risk of cardiac disorders, while enzalutamide has a higher probability of causing hypertension. Clinicians should consider these different adverse effects when choosing novel hormonal agents for patients with castration-resistant prostate cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.

Author: AlyamaniMohammad, EmamekhooHamid, ParkSunho, TaylorJennifer, AlmassiNima, UpadhyaySunil, TylerAllison, BerkMichael P, HuBo, HwangTae Hyun, FiggWilliam Douglas, PeerCody J, ChienCaly, KoshkinVadim S, MendirattaPrateek, GrivasPetros, RiniBrian, GarciaJorge, AuchusRichard J, SharifiNima

Faster resistance to castration
Sensitivity to extragonadal androgen synthesis inhibition
Androgen receptor stimulation

Patients with a common germline variant in HSD3B1(1245A>C) may experience increased 3-keto-5α-abiraterone synthesis, which could impact the efficacy of abiraterone treatment for prostate cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Video-Audio MediaMedia that combines video and audio. Includes movies, TV shows, and online videos.

Language : English

7.

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.

Author: MoreiraRaphael B, DebiasiMarcio, FranciniEdoardo, NuzzoPier V, VelascoGuillermo De, MalufFernando C, FayAndre P, BellmuntJoaquim, ChoueiriToni K, SchutzFabio A

mCRPC treatment
Drug side effects

This meta-analysis compared the risk of adverse events associated with abiraterone and enzalutamide, two drugs approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials.

Author: RizzoSergio, GalvanoAntonio, PantanoFrancesco, IulianiMichele, VincenziBruno, PassigliaFrancesco, SpotoSilvia, ToniniGiuseppe, BazanViviana, RussoAntonio, SantiniDaniele

Delay bone progression

Abiraterone acetate and enzalutamide, two drugs for metastatic castration-resistant prostate cancer (mCRPC), were compared indirectly for their effects on radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). Both drugs showed similar improvements in bone-related endpoints.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.

Author: ChiKim N, SpratlinJennifer, KollmannsbergerChristian, NorthScott, PankrasCatherine, GonzalezMartha, BernardApexa, StieltjesHans, PengLixian, JiaoJames, AcharyaMilin, KheohThian, GriffinThomas W, YuMargaret K, ChienCaly, TranNam Phuong

Prostate cancer treatment

Food significantly increases the bioavailability of abiraterone acetate. High-fat meals increase the AUC of abiraterone by approximately 2-fold compared to a modified fasting state. The drug is safe and well-tolerated with both high-fat and low-fat meals.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment.

Author: IulianiMichele, PantanoFrancesco, ButtiglieroConsuelo, FioramontiMarco, BertagliaValentina, VincenziBruno, ZoccoliAlice, RibelliGiulia, TucciMarcello, VignaniFrancesca, BerrutiAlfredo, ScagliottiGiorgio Vittorio, ToniniGiuseppe, SantiniDaniele

anti-resorptive activity
bone anabolism
skeletal event delay
survival advantage

The study evaluated a potential direct effect of abiraterone acetate (ABI) on human primary osteoclasts/osteoblasts (OCLs/OBLs).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.

Author: FranciniEdoardo, PetrioliRoberto, FiaschiAnna Ida, LaeraLetizia, RovielloGiandomenico

Prostate cancer treatment
Renal function improvement

This report presents 2 cases of metastatic castration-resistant prostate cancer and chronic kidney disease, both of which exhibited improvements in renal function with good response of the disease after treatment with abiraterone acetate.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

Author: EfstathiouEleni, TitusMark, TsavachidouDimitra, TzelepiVassiliki, WenSijin, HoangAnh, MolinaArturo, ChieffoNicole, SmithLisa A, KarlouMaria, TroncosoPatricia, LogothetisChristopher J

Sustained testosterone suppression
Limited ability to determine origin of testosterone

Abiraterone acetate achieved sustained suppression of testosterone in both blood and bone marrow aspirate to less than picograms-per-milliliter levels. Homogeneous, intense nuclear expression of androgen receptor (AR) combined with ≥ 10% CYP17 tumor expression was correlated with longer time to treatment discontinuation in patients with castrate-resistant prostate cancer (CRPC).

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.